Form 4/A for STOK Stoke Therapeutics, Inc.
Accepted 2024-12-10 00:00:00 ET · period of report 2024-12-03 · accession 0001415889-24-028889 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DA | 2024-12-10 | 2024-12-03 | STOK | Kaye Edward M. MD | CEO, Dir | M - OptEx | $0.00 | +26.2K | 74.8K | +54% | $0 |
| DA | 2024-12-10 | 2024-12-03 | STOK | Kaye Edward M. MD | CEO, Dir | M - OptEx | $0.00 | -26.2K | 26.2K | -50% | $0 |
| DA | 2024-12-10 | 2024-12-03 | STOK | Kaye Edward M. MD | CEO, Dir | A - Grant | $0.00 | +52.5K | 52.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-12-03 | M | A | 26,250 | $0.00 | 74,841 | D | — | — | |
| 2 | Derivative | Performance Stock Units | 2024-12-03 | M | D | 26,250 | $0.00 | 26,250 | D | — · — to 2025-12-03 | 26,250 Common Stock | (F1) Each performance stock unit represents a right to receive one share of the Issuer's common stock. (F3) Half the award vests on December 3, 2024 and the remainder shall vest on December 3, 2025, subject to the reporting person's continued service to the Issuer on the relevant vesting date. |
| 3 | Derivative | Performance Stock Units | 2024-12-03 | A | A | 52,500 | $0.00 | 52,500 | D | — · — to 2025-12-03 | 52,500 Common Stock | (F1) Each performance stock unit represents a right to receive one share of the Issuer's common stock. (F3) Half the award vests on December 3, 2024 and the remainder shall vest on December 3, 2025, subject to the reporting person's continued service to the Issuer on the relevant vesting date. |